Consensus Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:54:23 02/09/26 am AEST			5-day change	1st Jan Change
2.425 ^USD	+7.30%		+1.91%	+54.17%

07/08	Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09/07	Wall Street Ignores the Sirens

Evolution of the Average Target: Alector, Inc.

Evolution of the Target Price: Alector, Inc.

Changes in Analyst Recommendations: Alector, Inc.

ba1d169ac7d45cb.Tv2eruD_njxH5TNUA8g96OOZefxoYv8ezekFELOS8Wk.L5P85pG-zU8kh0QySKV2m4_LSbU3Lstd_JkyWsTDpzMRmvnNo7XaeRa3XA~d2de3ce780b853a79942c8788a925a67

Analysts' recommendations: Alector, Inc.

16/04	Alector Shares Rise After Cantor Fitzgerald Upgrade	MT
15/04	Cantor Fitzgerald Upgrades Alector to Overweight From Neutral	MT
11/03	Alector Shares Rise After BTIG Upgrade	MT
10/03	BTIG Upgrades Alector to Buy From Neutral, Price Target is $6	MT
23/10/25	Top Midday Decliners	MT
22/10/25	William Blair Downgrades Alector to Market Perform From Outperform	MT
22/10/25	TD Cowen Downgrades Alector to Hold From Buy	MT
22/10/25	BTIG Downgrades Alector to Neutral From Buy	MT
22/10/25	Cantor Fitzgerald Downgrades Alector to Neutral From Overweight	MT
22/10/25	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $1.50 From $3.50	MT
29/07/25	Alector Shares Rise After Mizuho Upgrade	MT
28/07/25	Mizuho Upgrades Alector to Outperform From Neutral, Raises Price Target to $3.50 From $2.50	MT
17/12/24	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $2.50 From $9	MT
16/12/24	Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15	MT
04/12/24	BofA Securities Downgrades Alector to Underperform	MT
14/12/23	Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	MT
13/12/23	Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	MT
16/11/23	Mizuho Securities Trims Price Target on Alector to $9 From $10, Keeps Buy Rating	MT
22/09/23	Cantor Fitzgerald Starts Alector at Overweight With $13 Price Target	MT
11/08/23	Mizuho Cuts Price Target on Alector to $10 From $12, Keeps Buy Rating	MT
09/08/23	Stifel Adjusts Price Target on Alector to $8 From $10, Maintains Hold Rating	MT
06/05/23	Barclays Adjusts Price Target on Alector to $12 From $14, Maintains Overweight Rating	MT
04/03/23	Morgan Stanley Adjusts Price Target on Alector to $10 From $11, Maintains Equal-Weight Rating	MT
03/03/23	BTIG Adjusts Price Target on Alector to $16 From $54, Keeps Buy Rating	MT
03/03/23	Mizuho Adjusts Price Target on Alector to $12 From $15, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALECTOR, INC.					+37.17%
	WUXI APPTEC CO., LTD.					+18.83%
	ARGENX SE					+12.23%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.45%
	INSMED INCORPORATED					+64.33%
	BIONTECH SE					+18.32%
	PHARMAESSENTIA CORPORATION					-3.81%
	GENMAB A/S					+14.38%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.38%
	EXELIXIS, INC.					-1.74%
	Average					+20.05%
	Weighted average by Cap.					+18.93%